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Abstract: A “Meeting on Upstream Rotavirus Vaccines and Emerging Vaccine Producers” 
was held at the World Health Organization in Geneva, Switzerland on March 28–30, 2006. 
The purpose was to discuss, evaluate, and weigh the importance of additional rotavirus vaccine 
candidates following the successful international licensure of rotavirus vaccines by two major 
pharmaceutical companies (GlaxoSmithKline and Merck) that had been in development for 
many years. Both licensed vaccines are composed of live rotaviruses that are delivered orally as 
have been all candidate rotavirus vaccines evaluated in humans. Each is built on the experience 
gained with previous candidates whose development had either been discontinued or, in the case 
of the previously licensed rhesus rotavirus reassortant vaccine (Rotashield), was withdrawn by 
its manufacturer after the discovery of a rare association with intussusception. Although which 
alternative candidate vaccines should be supported for development and where this should be 
done are controversial topics, there was general agreement expressed at the Geneva meeting 
that further development of alternative candidates is a high priority. This development will help 
insure that the most safe, effective and economic vaccines are available to children in Third 
World nations where the vast majority of the  600,000 deaths due to rotavirus occur each year. 
This review is intended to provide the history and present status of rotavirus vaccines as well 
as a perspective on the future development of candidate vaccines as a means of promulgating 
plans suggested at the Geneva meeting.
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Introduction
In January, 2006, reports on the safety and efﬁ  cacy of two rotavirus vaccine candi-
dates, that had recently been or were about to be licensed in several countries, were 
published back-to-back in The New England Journal of Medicine (Ruiz-Palacios 
et al 2006; Vesikari et al 2006). These reports represented the combined efforts of 
many hundreds of investigators, the cooperation of many thousands of study subjects 
and their parents, and the expenditure of several billion dollars by funding agencies 
and pharmaceutical companies. They also represented at least a temporary crest in 
the roller coaster ride that led to their development. The question now is, will this 
ride continue upward with these candidate vaccines and, if so, should it be joined by 
alternative rotavirus vaccine candidates. One purpose of this review is to list notable 
events that occurred over the past 60 years which have contributed to the successful 
licensure of these two vaccines. The second purpose is to describe the most viable 
alternative rotavirus vaccine candidates with particular emphasis on answering the 
question of why they are needed.
Discovery of rotavirus and its associated disease
The ﬁ  rst rotaviruses to be described, based on pathology and epidemiology, were 
murine strains which were classiﬁ  ed under the general description as the agents Therapeutics and Clinical Risk Management 2008:4(1) 50
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responsible for “epizootic diarrhea of infant mice” ie, EDIM 
(Cheever and Mueller 1947; Pappenheimer and Enders 1947). 
Murine rotaviruses were also among the ﬁ  rst to be visualized 
by electron microscopy (Adams and Kraft 1963). Viruses 
with comparable morphologic features were observed in that 
same year in rectal swab specimens of monkeys (Malherbe 
and Harwin 1963). These agents were described as 70-nm 
particles that had a wheel-like appearance and, hence, were 
later designated “rota” viruses from the Latin word for wheel 
(Flewett et al 1974; Wyatt et al 1978). In 1969, Mebus et al 
(1969) demonstrated the presence of these particles in stools 
of calves with diarrhea, thus associating these viruses with 
a diarrheal disease in cattle. The correlation between these 
viruses and severe diarrhea in young children was reported 
ﬁ  rst in 1973 by Bishop et al (1973) who used electron micros-
copy to examine biopsy specimens of duodenal mucosa from 
children with acute gastroenteritis. Within a short time, these 
and other investigators conﬁ  rmed the association between the 
presence of rotavirus in feces and acute gastroenteritis.
In addition to their distinctive morphologic features, human 
rotaviruses along with their animal counterparts were shown to 
share a group antigen (Kapikian et al 1976; Woode et al 1976) 
and were classiﬁ  ed as members of the Rotavirus genus within 
the Reoviridae family (Matthews 1979). In 1980, particles 
that were indistinguishable morphologically from established 
rotavirus strains but lacked the common group antigen were 
discovered in pigs (Bridger 1980; Saif et al 1980). This ﬁ  nding 
subsequently led to the identiﬁ  cation of rotaviruses belonging 
to six additional groups (B to G) based on common group 
antigens, with the original rotavirus strains classiﬁ  ed as group 
A (Saif and Jiang 1994). Only groups A to C have been associ-
ated with human diseases, and most known cases of rotavirus 
gastroenteritis have been caused by group A strains.
Today, rotaviruses are recognized as the primary cause 
of severe infantile gastroenteritis worldwide (de Zoysa and 
Feachem 1985). In the United States, as in other developed 
countries, these viruses are responsible for numerous hospital-
izations in young children but are estimated to cause relatively 
few deaths (Glass et al 1991, 2006). On a world scale, however, 
rotaviruses are believed to be the cause of  600,000 deaths 
each year (Glass et al 2006; Parashar et al 2006). For these 
reasons, rotaviruses have received a high priority as a target 
for vaccine development (Institute of Medicine 1986; Research 
priorities for diarrheal diseases vaccines 1991; GAVI 2001).
What is rotavirus?
A computer-generated image of the rotavirus particle 
obtained by cryoelectron microscopy (Figure 1) showed 
that it is approximately 100 nm in diameter and has a capsid 
composed of three concentric protein layers (Shaw et al 
1993; Prasad and Chiu 1994). The outer layer contains the 
VP7 glycoprotein (780 molecules/virion) and 60 dimers 
or trimers of the VP4 protein (Yoder and Dormitzer 2006), 
the latter of which forms spikelike projections that extend 
through and 11–12 nm beyond the VP7 layer (Prasad and 
Chiu 1994; Shaw et al 1993; Yeager et al 1994). Cleavage 
of the VP4 protein prior to cell attachment by trypsin-like 
enzymes into two peptide fragments (VP5* and VP8*) 
that remain associated with the virus particle enhances its 
infectivity. The VP4 protein is anchored to the intermediate 
layer of the particle composed of 780 molecules of the VP6 
protein. The innermost layer contains 120 molecules of the 
VP2 protein that interact with 12 molecules each of the viral 
transcriptase (VP1) and guanylyltransferase (VP3) along with 
the 11 segments of double-stranded RNA genome. These seg-
ments encode the 6 structural proteins of the virus as well as 
6 non-structural proteins designated NSP1-NSP6 (Table 1). 
The smallest segment encodes both NSP5 and NSP6. The 
genome segments range in size from ca. 660 to 3300 base 
pairs; their encoded proteins, the functions of which are at 
least partially understood, have molecular weights of ca. 
12,000 to 125,000.
The genome segments of rotavirus can be extracted 
from viral particles and separated by polyacrylamide gel 
electrophoresis into 11 distinct bands visualized by ethidium 
bromide or silver staining (Figure 2). Each rotavirus strain has 
a characteristic RNA proﬁ  le or electropherotype, a property 
that has been used extensively in epidemiologic studies of 
these viruses. The characteristic RNA electrophoretic pattern 
of group A rotaviruses consists of four size classes containing 
segments 1–4, 5 and 6, 7–9, and 10 and 11. RNA segments of 
strains belonging to less well characterized rotavirus groups 
(ie, groups B to G) also can be separated into size classes, 
but the distribution of segments within these classes differs 
from group to group.
Serotypes of rotavirus
Both outer capsid proteins of rotavirus, VP4 and VP7, contain 
neutralization epitopes and, thereby, both are involved in 
serotype determination, an important consideration in vac-
cine development. Originally, serotyping was based solely 
on differences in the VP7 protein because when animals were 
hyperimmunized with rotaviruses they developed almost all 
neutralizing antibody to this protein and cross-neutralization 
studies conducted with these hyperimmune sera readily 
separated the strains into VP7 serotypes (Hoshino et al 1984; Therapeutics and Clinical Risk Management 2008:4(1) 51
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Wyatt et al 1982). When it was found later that VP4 could, 
in some cases, be the dominant neutralization protein (Ward 
et al 1988, 1993), a dual serotyping scheme was required. 
Although VP7 serotypes could be determined readily by 
cross-neutralization studies, this was more difﬁ  cult for VP4 
(Taniguchi et al 1988; Gorziglia et al 1990; Padilla-Noriega 
et al 1992; Snodgrass et al 1992). Therefore, two numeric 
systems were devised to classify the VP4 protein in rotavirus 
strains. One is based on comparative nucleic acid hybridiza-
tion and sequence analyses (genotypes), and the second is 
based on neutralization (serotypes) using antisera against 
baculovirus-expressed VP4 proteins or reassortants with 
speciﬁ  c VP4 genes. Genotypes of VP4 are designated by 
brackets while serotypes are not. Rotavirus classiﬁ  cation 
Figure 1 Computer-generated image of the triple-shelled rotavirus particle obtained by cryoelectron microscopy. The cut-away diagram shows the outer capsid composed 
of VP4 spikes and VP7 shell, intermediate VP6 shell, and inner VP2 shell surrounding the core containing the 11 double-stranded RNA segments and VP1 and VP3 proteins. 
(Courtesy of Dr. B. V. V. Prasad, Baylor College of Medicine, Houston, TX.)Therapeutics and Clinical Risk Management 2008:4(1) 52
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based on VP4 and VP7 is designated P and G types to 
describe the protease sensitivity and glycosylated structure 
of these two proteins, respectively. Thus, the full designation 
for the most common serotype/genotype of human rotavirus 
is G1P1A[8]. Today, 15 G types and 26 P types have been 
described but only 5 G serotypes (G1, G2, G3, G4, and G9) 
and 3 P genotypes (P[4], P[6], and P[8]) are commonly 
associated with human rotavirus illnesses.
Mechanisms of immunity
to rotavirus
An obvious place to begin to understand rotavirus immunity 
is to determine the effectiveness of previous rotavirus infec-
tions in prevention of subsequent infections and disease. 
Many investigators have reported that natural rotavirus 
infections in humans produce incomplete protection, but 
little doubt exists that previous infections protect against 
severe disease associated with reinfection. In probably 
the most thorough study reported, protection against both 
reinfection and diarrhea increased with each new rotavirus 
infection but protection against severe rotavirus disease 
was nearly complete after a single rotavirus infection, even 
in the face of several circulating G serotypes of the virus 
(Velazquez et al 1996). Sequential infections even with the 
same serotype clearly occur but less regularly than with dif-
ferent serotypes. Thus, there is conﬂ  icting data regarding the 
association between serotype-speciﬁ  c neutralizing antibody 
and protection. Active immunity against both homotypic and 
heterotypic rotaviruses has also been demonstrated in mice, 
calves, and rabbits after single rotavirus infections, further 
indicating something in addition to neutralizing antibody is 
important in protection (Bridger and Oldham 1987; Woode 
et al 1987; Ward et al 1992; Conner et al 1993)
The immunological effectors that prevent rotavirus disease 
have been partially identiﬁ  ed, particularly through studies 
with animal models, but in humans remain poorly understood. 
Because rotaviruses replicate in intestinal enterocytes, result-
ing in the associated gastrointestinal symptoms, it is gener-
ally assumed that effector mechanisms must be active at the 
intestinal mucosa. The most obvious immunological effector 
is secretory IgA. In agreement with this suggestion, protec-
tion against rotavirus infection in orally immunized mice was 
found to correlate with levels of fecal and serum rotavirus IgA 
but not serum rotavirus IgG (Feng et al 1994; McNeal et al 
1994). In humans, titers of serum and intestinal rotavirus IgA 
as well as serum rotavirus IgG were reported to correlate with 
protection following natural infection (Chiba et al 1986; Ward 
et al 1989; Clemens et al 1992; Coulson et al 1992; Matson 
et al 1993; O’Ryan et al 1994; Velazquez et al 2000).
The most immunogenic rotavirus protein is VP6 but 
it does not stimulate neutralizing antibodies. It has been 
reported, however, that IgA antibodies directed at VP6 can 
be protective by mechanisms that are not completely under-
stood but may involve intracellular inhibition of rotavirus 
replication within infected enterocytes during polymeric 
antibody transport to the intestinal lumen (Burns et al 1996; 
Feng et al 2002; Corthesy et al 2006). Antibodies directed at 
either the VP4 or the VP7 proteins can neutralize virus and 
are believed to provide protection by classical neutralization. 
Both proteins can also induce type-speciﬁ  c and cross-reactive 
serotype responses (Mackow et al 1988; Morita et al 1988; 
Taniguchi et al 1988; Gorziglia et al 1990).
Table 1 Sizes of rotavirus gene segments and properties of 
encoded proteins
RNA  Encoded  Properties of proteins
segment protein
1  VP1  Inner core protein
  RNA  binding
  RNA  transcriptase
2  VP2  Inner capsid protein
  RNA  binding
3  VP3  Inner core protein
  Guanylyltransferase
  Methyltransferase
4  VP4  Outer capsid protein
  Hemagglutinin
  Neutralization  protein
  Receptor  binding
  Fusogenic  protein
5 NSP1  Nonstructural  protein
  RNA  binding
    IRF regulatory protein
6 VP6  Intermediate  capsid
    Group and subgroup antigen
7 NSP3  Nonstructural  protein
  RNA  binding
  Translational  control
8 NSP2  Nonstructural  protein
    RNA and NSP5 binding
  Virosome  formation
9  VP7  Outer capsid glycoprotein
  Neutralization  protein
10 NSP4  Nonstructural  glycoprotein
  Transmembrane  protein
  Enterotoxin
11 NSP5  Nonstructural  protein
  Phosporylated
    NSP2 and NSP6 binding
12 NSP6  Nonstructural  protein
  NSP5  binding
Modiﬁ  ed from Estes and Kapikian (2007).Therapeutics and Clinical Risk Management 2008:4(1) 53
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Gene knockout mice have been used to distinguish the 
roles of CD8+ T cells and antibody in protection. Rotavirus-
speciﬁ  c cytotoxic T lymphocytes recognize epitopes on 
several rotavirus proteins which are generally not serotype 
speciﬁ  c (Ofﬁ  t and Dudzik 1988; Ofﬁ  t et al 1991; Franco 
et al 1994). Adoptive transfer of splenic lymphocytes from 
mice infected with homologous or heterologous rotavirus 
strains can protect suckling mice and protection appeared to 
depend on the presence of CD8+ T lymphocytes (Ofﬁ  t and 
Dudzik 1990). Similarly, CD8+ splenic or intraepithelial T 
lymphocytes obtained from the intestine of rotavirus-infected 
mice can eliminate the chronic rotavirus shedding seen in 
SCID mice (Dharakul et al 1990). Other studies revealed 
that adoptive transfer of splenic CD4+ T cells from mice 
intranasally immunized with a recombinant VP6 protein 
resolved shedding in chronically infected, immunodeﬁ  cient 
Rag-2 mice (McNeal et al 2002). Therefore, either CD8+ or 
CD4+ T cells are capable of resolving rotavirus infections. 
Possible roles of these cells in resolution or prevention of 
human rotavirus infections remain to be determined.
Although cytolytic CD8+cells were found to be important 
for resolution of a rotavirus infection, only antibody was 
shown to provide protection against a subsequent challenge 
(Franco and Greenberg 1995; McNeal et al 1995; Franco et al 
1997). A recent study in mice revealed that oral immuniza-
tion of mice with a rotavirus that was fully heterotypic to the 
challenge strain provided nearly complete protection against 
fecal rotavirus shedding but this protection was dependent 
on the ability of antibody to be transported through intestinal 
epithelial cells (VanCott et al 2006). This result supports the 
earlier suggestion that heterotypic protection after live virus 
immunization may be due to intracellular inhibition of virus 
replication, at least in mice (Burns et al 1996; Feng et al 
2002; Corthesy et al 2006). These results indicate that the 
levels, location, and targets of antibody are all of immediate 
importance in protection against rotavirus. These ﬁ  ndings 
have important implications for vaccine development
Experiences gained from the early 
rotavirus vaccine candidates
Because natural rotavirus infections induce excellent protec-
tion, at least against severe rotavirus disease, vaccine efforts 
have been directed mostly at the development of live attenu-
ated rotavirus vaccines. Initial studies concentrated on the use 
of animal rotavirus strains, labeled the Jennerian approach 
(Kapikian et al 1986) because it relies on the natural attenuation 
of animal viruses in humans for safety, and largely heterotypic 
immune responses for protection. Just 10 years after the identi-
ﬁ  cation of rotavirus as the primary agent of severe diarrhea in 
young children, the ﬁ  rst vaccine trials were performed using 
RIT 4237, a G6P[1] bovine rotavirus (Vesikari et al 1983). 
This vaccine was safe and effective in Finland, and provided 
protective efﬁ  cacy of  80% against severe rotavirus disease 
due to heterotypic human rotaviruses (Vesikari et al 1985). 
However, later studies in developing countries were disappoint-
ing, (DeMol et al 1986; Hanlon et al 1987; Lanata et al 1989) 
Figure 2 Polyacrylamide gel electrophoretic patterns of genomic RNAs obtained 
from group A human rotaviruses and visualized by silver staining. The patterns
demonstrate the characteristic four size classes of RNA separated into groups of
4, 2, 3, and 2 segments each. Human rotavirus strains included (from left to right) 
lane 1, Wa; lane 2, 248 strain; lane 3, 456 strain; lane 4, DS-1; lane 5, Wa.Therapeutics and Clinical Risk Management 2008:4(1) 54
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showing little or no efﬁ  cacy, thus causing the termination of 
studies with this vaccine.
Initial studies with WC3, a G6P[5] bovine rotavirus 
developed as a vaccine candidate a short time later, also 
appeared promising (Clark et al 1988). However, subsequent 
trials did not show signiﬁ  cant protection (Bernstein et al 
1990; Georges-Courbot et al 1991), and studies with this 
candidate vaccine were also terminated. In an attempt to make 
the WC3 vaccine more serotypically related to human strains, 
genes encoding the VP4 and VP7 neutralization proteins 
from human rotaviruses were introduced into WC3 by gene 
reassortment. This method, labeled the modiﬁ  ed Jennerian 
approach (Flores and Kapikian 1990), resulted in the develop-
ment of the pentavalent RotaTeqTM vaccine, one of the two 
rotavirus vaccines being licensed in the world today.
A simian rotavirus called rhesus rotavirus (RRV) was 
also developed as one of the ﬁ  rst vaccine candidates but 
protection elicited by this vaccine was likewise inconsistent 
(Flores et al 1987; Vesikari et al 1990; Santosham et al 
1991; Madore et al 1992; Padilla-Noriega et al 1992). The 
G serotype of the G3P[3] RRV strain is shared with human 
rotaviruses and can be the dominant circulating strains, and 
protection elicited by RRV appeared to be more effective 
when this was the case. As a result, RRV was reassorted 
with human strains to incorporate VP7 genes of the other 
three dominant human G serotypes (G1, G2, and G4), thus 
creating the tetravalent RotashieldTM vaccine (Figure 3). 
This vaccine was licensed and incorporated into the USA 
infant immunization program in 1998 but was withdrawn by 
its manufacturer in 1999 after the discovery of a small but 
signiﬁ  cant increase in intussusception in vaccinees during 
post-licensure surveillance (Murphy et al 2003).
The only other vaccine candidate developed directly from 
an animal strain and tested in humans was the G10P[12] lamb 
strain. This virus was administered to  1,000 children (aged 
6–24 months) in a Phase II trial with no evidence of side 
effects (GAVI 2001). Although no controlled efﬁ  cacy trials 
with this vaccine have been reported, it is presently licensed 
and being sold in the private market in China.
Two rotavirus vaccines are being 
licensed worldwide today
The ﬁ  rst licensure of a rotavirus vaccine after the with-
drawal of Rotashield in 1999 occurred in Mexico in 2004 
and the vaccine became available there in January, 2005. 
This was the attenuated human RotarixTM vaccine that was 
produced by GlaxoSmithKline. Since that time, the vaccine 
has been licensed in nearly 100 countries, including those 
in the European Union, is being used in routine childhood 
vaccination in at least 7 nations, and has been pre-qualiﬁ  ed 
for procurement by U.N. agencies by the World Health 
Organization. This vaccine is based on the attenuated human 
strain, 89–12, a G1P[8] strain which is the most common 
serotype worldwide. The virus was initially obtained from 
an infant with rotavirus gastroenteritis (Bernstein et al 1998), 
and attenuated by multiple passages in tissue culture. Studies 
showed the 89–12 vaccine was safe, although it induced a low 
Figure 3 Polyacrylamide gel electrophoretic patterns of the genome segments 
from RRV and the G1, G2, and G4 reassortant strains that compose the tetravalent 
RRV-based vaccine (Rotashield). The strains all contain 10 RRV genes and differ only in 
the gene segment encoding the VP7 protein, which migrates in the seventh (RRV) or 
ninth (reassortants) position, as designated by arrowheads.Therapeutics and Clinical Risk Management 2008:4(1) 55
Alternative rotavirus vaccines
grade fever in 19% of recipients, and two doses provided 89% 
protection against any rotavirus disease, and 100% protection 
from more serious disease (Bernstein et al 1999).
The 89–12 strain was puriﬁ  ed by limiting dilution and 
further passaged in tissue culture. The ﬁ  nal product, ini-
tially called RIX4414 and later marketed as RotarixTM, was 
evaluated in several studies. Initial safety testing (Vesikari, 
Karvonen, Korhonen et al 2004) revealed the vaccine was 
safe and did not induce the fever that was seen following 
vaccination with its 89–12 parent. Subsequent reports from 
Singapore (Phua et al 2005), Finland (Vesikari, Karvonen, 
Puustinen et al 2004), Latin America (Ruiz-Palacios et al 
2006), and the USA (Dennehy et al 2005) conﬁ  rmed the 
safety, veriﬁ  ed the vaccine was not associated with fever, 
and reported that the vaccine remained highly immunogenic. 
Thus, the additional passages and/or limiting dilution puriﬁ  -
cation resulted in a vaccine strain that has been consistently 
non-reactogenic. The vaccine also did not interfere with the 
immune responses to the other concomitantly used vaccines 
including OPV (Dennehy et al 2005; Ruiz-Palacios et al 
2006). In the initial efﬁ  cacy trial of RIX 4414 conducted in 
Finland over two rotavirus seasons, the vaccine was 73% pro-
tective against all rotavirus gastroenteritis and 90% protective 
against severe gastroenteritis despite the relatively low dose of 
vaccine used (Vesikari, Karvonen, Puustinen et al 2004).
Because of the association of Rotashield with intussuscep-
tion, the next rotavirus vaccines were required to undergo very 
large safety trials. Rotarix was, therefore, evaluated in a very 
large safety trial (Ruiz-Palacios et al 2006). In a study of over 
63,000 infants conducted primarily in several countries in Latin 
America, the vaccine was safe and did not induce fever and, 
most importantly, was not associated with intussusception. 
In this large study, efﬁ  cacy was 85% against severe rotavirus 
diarrhea and hospitalizations, and reached 100% against more 
severe gastroenteritis. Of note, efﬁ  cacy was high (over 86%) 
against severe rotavirus diarrhea caused not only by G1P[8] 
strains but also by the VP4 related G3P[8], G4P[8] and G9P[8] 
strains. Efﬁ  cacy against G2P[4] strains in the few subjects 
infected with these viruses was less, 41.0%. However, in 
meta-analyses conducted with the data from several studies, 
the efﬁ  cacy was 67%–71% indicating that the vaccine will be 
efﬁ  cacious against strains that are serotypically dissimilar in 
both their VP4 and VP7 proteins (Ruiz-Palacios et al 2006; 
Vesikari, Karvonen, Korhonen, et al 2006). In the most recent 
trial of over 4,000 infants conducted in six European countries, 
protection was 87% against any rotavirus gastroenteritis, 
96% against severe disease and 100% against hospitalization 
due to rotavirus (Vesikari, Karvonen, Korhonen et al 2006).
In this study, efﬁ  cacies against G3, G4 and G9 rotaviruses were 
similar to that against G1 and exceeded 95% while efﬁ  cacy 
against G2 strains was 75%. Of importance, efﬁ  cacy against 
hospitalization due to gastroenteritis of any cause was 75%.
In 2006, the pentavalent WC3-based reassortant vaccine, 
Rotateq™, was also licensed, ﬁ  rst in the USA and subsequently 
in the European Union and other international settings by 
Merck. After the WC3 vaccine was shown to be safe but not 
consistently effective (Clark et al 1988; Bernstein et al 1990; 
Georges-Courbot et al 1991), a monovalent vaccine containing 
the VP7 protein of a human G1 rotavirus was developed. This 
vaccine was reported to be protective, especially against more 
severe disease, during a predominantly serotype G1 outbreak 
in the USA (Clark et al 1990; Treanor et al 1995). Next, a 
WC3-based reassortant quadrivalent vaccine including both 
VP7 and VP4 human rotavirus gene substitutions, ie, G1, G2, 
G3, or P[8], was evaluated. In studies conducted at multiple 
centers in the United States, it was shown to be safe and effec-
tive against all cases of rotavirus gastroenteritis (75%) and 
especially against severe cases (100%) (Clark et al 2004). The 
ﬁ  nal pentavalent Rotateq vaccine contains the VP7 and VP4 
reassortants found in the quadrivalent vaccine plus a VP7 G4 
reassortant (Clark et al 2006).
Again, because of the association of Rotashield with intus-
susception, this rotavirus vaccine was also required to undergo 
very large safety trials. Accordingly, a study was conducted 
with RotaTeq in >70,000 infants, primarily in Finland and the 
USA, which showed that the vaccine was safe and induced no 
fever (Vesikari, Matson et al 2006). Most importantly, there 
was no association with intussusception. The vaccine was also 
highly effective, reducing all cases of G1–G4 rotavirus gastro-
enteritis by 74.0%, severe gastroenteritis by 98.0%, and hospi-
talizations and emergency room visits by 94.5%. Interestingly, 
the efﬁ  cacy of the vaccine against all gastroenteritis-related 
hospitalizations after the ﬁ  rst dose was 58.9%. Therefore, as 
was also found after Rotarix vaccination, overall protection 
against severe gastroenteritis seemed greater than expected 
based solely on rotavirus infections. Reasons for this have not 
been established but it is likely that either the percentage of 
hospitalizations due to rotavirus are greater than expected or 
vaccination provides a general boost in immunity that protects 
against more than just rotavirus disease.
What alternative rotavirus vaccine 
candidates are being most actively 
investigated?
Several other live, orally-deliverable rotavirus vaccine candi-
dates are under development, some for many years, but these Therapeutics and Clinical Risk Management 2008:4(1) 56
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had not been put on the fast-track with Rotarix or RotaTeq. 
However, with new and improved funding from donor agen-
cies along with greater national and international appreciation 
for the importance of rotavirus as a deadly pathogen, this 
picture is changing. In addition, several non-living rotavirus 
vaccine candidates have been developed and tested in animal 
models but none have been evaluated in humans. Studies on 
the best known live and non-living alternative rotavirus vac-
cine candidates will now be described along with the status 
of their development.
Alternative live rotavirus vaccine 
candidates
Although several live rotavirus vaccine candidates are under 
development for potential national or regional usage, three 
alternative candidates appear to presently have the most 
potential for broader usage (Table 2). These three [the bovine 
(UK strain)/human reassortant vaccine, the human neonatal 
RV3 strain, and the bovine/human neonatal 116E strain] have 
all been under development for many years, but progress with 
each has been delayed for its own unique reasons.
The bovine (UK) reassortant vaccine was developed in 
the laboratory of Albert Kapikian of the National Institutes of 
Health in Bethesda, Maryland, together with the RRV-based 
tetravalent vaccine that became Rotashield. One reason to 
concentrate on the simian rotavirus-based vaccine at the 
expense of the bovine rotavirus-based candidate was the sero-
types of the two strains. The bovine strain was serotypically 
unrelated to relevant human rotaviruses while RRV shared 
its G serotype (G3) with one of the four dominant human 
rotavirus types. The decision to focus on the RRV strain had 
one of the greatest impacts of any made during rotavirus 
vaccine development. The RRV-based vaccine clearly had 
center-stage for years during the course of its evaluation, 
licensure, and subsequent incorporation into the childhood 
immunization series in the USA.
Even so, the tetravalent bovine (UK) reassortant vaccine, 
that contained single VP7 gene substitutions from G1, G2, 
G3 or G4 human rotaviruses on a 10-gene UK background, 
was evaluated initially for safety and immunogenicity in the 
USA (Clements-Mann et al 1999) and later for safety/immu-
nogenicity/efﬁ  cacy in Finland (Vesikari, Karvonen, Majuri, 
et al 2006) before the withdrawal of Rotashield. Although 
the studies were small (161 vaccinees and 80 placebo 
recipients in the efﬁ  cacy trial), protection was signiﬁ  cant 
(60% against any rotavirus disease and 90% against severe 
rotavirus disease; p   0.02). In order to facilitate the 
production and commercialization of this vaccine, the NIH 
Ofﬁ  ce of Technology Transfer has granted licenses to at least 
8 groups throughout the world, 7 of which are in developing 
nations, including vaccine manufacturers in Brazil, China 
and India.
RV3 is a G3P[6] human rotavirus that was isolated in an 
obstetric nursery in Melbourne, Australia, where it caused 
endemic, asymptomatic infections in newborn infants in 
the 1970s. Neonates infected with this virus were 100% 
protected against severe rotavirus disease, caused primarily 
by heterotypic G2P[4] strains, for their ﬁ  rst 3 years of life 
(Bishop et al 1983). Once RV3 was developed into a vaccine 
candidate, Phase I and early Phase II trials were conducted 
(Barnes et al 2002). Although an immune response to the 
vaccine was detected in only 46% of subjects, protection 
in the responders against primarily serotype G1 circulating 
rotaviruses was 54% (p = 0.08). It has been suggested that 
vaccine “take” may be improved if the dose is increased 
above the 6.5 × 105 tissue culture infectious viruses previ-
ously administered. Accordingly, the virus has been grown 
to a higher titer and plans are underway for its evaluation 
after administration of higher doses. The slow pace at which 
this vaccine has been developed is presumably related to its 
somewhat disappointing immunogenicity and the lack of 
interest from pharmaceutical companies. Both limitations 
may be corrected with the use of a higher titer virus. Current 
plans include development of the vaccine candidate with a 
vaccine manufacturer in Indonesia.
The 116E G9P[11] rotavirus strain was obtained from 
neonates who became asymptomatically-infected in New 
Delhi, India, in the mid-1980’s. Subjects who became 
infected were signiﬁ  cantly (p   0.05) protected against 
subsequent rotavirus diarrhea (Bhan et al 1993). 116E is 
a natural reassortant, deriving it VP4 gene segment from a 
bovine rotavirus and the other 10 genes from a human strain 
(Das et al 1993, 1994). During the same period that the 
116E strain was infecting neonates in New Delhi, another 
bovine/human reassortant was asymptomatically-infecting 
neonates in the Bangalore region of India. The G10PI I321 
Table 2   Alternative live rotavirus vaccine candidates
Candidate Origin  Status
UK reassortant  Developed at NIH  Phase I and
  Bovine reassortant containing G1,   early Phase II
  G2, G3, G4 human genes 
RV3  Human neonatal strain (G3P[6])   Phase I and
  isolated in Australia  early Phase II
116E  Natural bovine-human reassortant   Phase I and
  (G9P[11]) isolated in India  early Phase IITherapeutics and Clinical Risk Management 2008:4(1) 57
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strain isolated from these subjects derived 9 gene segments 
from a bovine rotavirus and only the segments for 2 non-
structural genes from a human strain (Dunn et al 1993). It 
was initially suggested that neonates infected with G10P[11] 
strains appeared to be protected against subsequent rotavi-
rus disease (Aijaz et al 1996), but a very recent report by 
another group of investigators suggests otherwise (Banerjee 
et al 2007). Regardless, the I321 strain was also developed 
into a vaccine candidate. However, when both 116E and 
I321 vaccines were tested for immunogenicity in a small, 
placebo-controlled trial, only the 116E strain was found to 
elicit signiﬁ  cant immune responses (Bhandari et al 2006). 
Therefore, the I321 strain was shelved and only the 116E 
strain is now being actively pursued as a vaccine candidate. 
Although vaccine preparations of both candidates were pre-
pared and initial human trials were initiated in Cincinnati, 
Ohio, in 1997, these trials were discontinued in 1998 due to 
concerns over the purity of the cells in which the vaccines 
were grown. These concerns were eventually alleviated and 
only then were trials with these vaccines continued, this time 
in India where the viruses were ﬁ  rst discovered (Bhandari 
et al 2006).
Non-living rotavirus vaccine candidates
The original expectation for successful live, orally-deliverable 
rotavirus vaccines was that they protect against almost all 
cases of rotavirus disease of any severity. This expectation 
has been modiﬁ  ed with the realization that even natural 
rotavirus infections do not provide complete protection 
against subsequent rotavirus illnesses. However, one natural 
infection has been reported to provide nearly complete (87%) 
protection against severe rotavirus disease and two infections 
were 100% protective (Velazquez et al 1996). Therefore, a 
more realistic goal for a successful live rotavirus vaccine is 
that it is able to consistently provide a high level of protec-
tion against severe rotavirus illnesses. This goal has so far 
been realized, where tested, for the rotavirus vaccines now 
being licensed and had been found for the Rotashield vac-
cine as well. However, no efﬁ  cacy trials with any of these 
three vaccines have been completed in Third World nations 
where rotavirus deaths are most common and where the ear-
lier rotavirus vaccine candidates failed to provide signiﬁ  cant 
protection.
Based on these observations regarding efﬁ  cacies and 
the not fully resolved safety concerns associated with live 
rotavirus vaccines, non-living rotavirus vaccines are being 
developed as possible next generation candidates. Although 
these range from fully intact, inactivated rotaviruses to pieces 
of rotavirus proteins, even to DNA vaccines, three types of 
candidates have been given the most attention. These include 
inactivated triple- and double-layered (lacking VP4 and 
VP7) rotavirus particles, triple- and double-layered virus-
like particles (VLPs), and recombinant, E. coli-expressed 
VP6 proteins (Table 3). Candidates representative of each of 
these 3 types have been under development since the 1980s 
and tested in animal models but, as already noted, none have 
been evaluated in humans.
Vaccination with inactivated rotavirus particles delivered 
by either parenteral or mucosal (intranasal) routes has been 
found to effectively block intestinal rotavirus replication 
in adult mice challenged with a murine rotavirus (McNeal 
et al 1998, 1999). In most cases, protection was enhanced 
Table 3 Alternative non-living rotavirus vaccine candidates
Candidate  Properties  Where tested  Level of protection
Inactivated virus  Viral particles inactivated   Tested in mice,   Effective in reducing or 
  by physical or chemical   rabbits and   preventing rotavirus shedding 
  methods  gnotobiotic piglets  with or without the use of 
     adjuvants.
Virus like particles   Particles formed from   Tested in mice,   Effective in reducing or 
(VLPs)  expressed recombinant   rabbits and   preventing rotavirus shedding 
  proteins. Contain VP2 and  gnotobiotic pigs  in mice and rabbits. Alone, 
   VP6 with or without VP4     not protective in gnotobiotic 
  and VP7    piglets. More effective with 
      an adjuvant. More effective 
      intranasally than orally. 
VP6  E. coli-expressed   Tested in mice  Effective in reducing or 
  recombinant protein    preventing rotavirus shedding 
      when given orally, 
      intranasally or intrarectally 
      with adjuvant to mice.Therapeutics and Clinical Risk Management 2008:4(1) 58
Ward et al
by co-immunization with an effective adjuvant. Fully intact, 
triple-layered particles were found to be more effective than 
double-layered particles only when their VP4 or VP7 protein 
matched the serotype of the challenge virus. This suggested 
that neutralizing antibodies played a role in protection but 
were not required for effective immunity. One formaldehyde-
inactivated, puriﬁ  ed rotavirus vaccine candidate, prepared 
from the G1P[4] AU64 strain, has been used to intramuscu-
larly immunize gnotobiotic piglets which were reported to 
be protected from fecal virus shedding following challenge 
with a G1P[8] human rotavirus (O. Nakagomi personal com-
munication). Other candidate vaccines were prepared by the 
Viral Gastroenteritis Laboratory of the Centers for Disease 
Control (Atlanta, GA), including G1P[8], G2P[4] and G9P[6] 
strains, and studies are being performed to determine their 
immunogenicities and efﬁ  cacies in mice, macaques, and 
gnotobiotic piglets (B Jiang personal communication).
The premier laboratory for studies on immunity and 
efficacy involving rotavirus immunization in gnotobi-
otic piglets has been that of Linda Saif (The Ohio State 
University, Wooster, OH), and one candidate vaccine that 
has been evaluated in her laboratory is the inactivated G1P[8] 
Wa strain of human rotavirus. Reports from these studies 
indicate that after either oral or intramuscular delivery of 
inactivated Wa to newborn piglets, intestinal IgA responses 
to the immunogen, as well as protection against intestinal 
fecal rotavirus production and diarrhea after challenge with 
virulent Wa virus, were signiﬁ  cantly less than found after 
oral vaccination with live Wa virus (To et al 1998; Yuan and 
Saif 2002). However, protection in this piglet model has been 
consistently less effective with all immunogens tested than 
found in adult mice. There are several explanations for this 
observation but, in the end, it will not be clear which model 
is more applicable to humans until the studies are performed 
in humans.
VLPs have been developed as possible vaccine candi-
dates for several viruses, and production of rotavirus VLPs 
was ﬁ  rst reported in the 1980s (Estes et al 1984; Ready and 
Sabara 1987; Crawford et al 1994). Any of several expres-
sion vectors can be used to produce the recombinant proteins 
that become incorporated into VLPs, but the most common 
is baculovirus and has been the expression vector of choice 
for rotavirus as well. One of the most viable candidate rota-
virus vaccines in the early 1990’s was composed of VLPs 
which underwent extensive preclinical testing. However, 
following several changes in ownership due to company 
acquisitions, this VLP vaccine was eventually licensed 
by the same company that was developing Rotashield. No 
signiﬁ  cant clinical progress with this or any other rotavirus 
VLP vaccine has occurred since that time but studies in 
animal models with candidate VLP vaccines have ﬂ  our-
ished. Some VLP vaccines contain only VP2 and VP6 (2/6 
VLPs) while others have incorporated one or more of the 
neutralization proteins, VP4 and VP7 (2/6/4/7 VLPs). Many 
recent animal studies have utilized 2/6 VLPs administered 
by mucosal routes together with effective adjuvants. Both 
intranasal and intrarectal immunization of mice with these 
particles has resulted in excellent protection against fecal 
rotavirus shedding following murine rotavirus challenge 
(O’Neal et al 1997, 1998; Agnello et al 2006). Intrarectal 
immunization of mice with VLPs containing the VP8* por-
tion of VP4 along with VP2, VP6 and VP7 also provided 
excellent protection in mice (Parez et al 2006). In contrast, 
gnotobiotic piglets intranasally-immunized with 2/6 VLPs 
were neither protected against fecal shedding of the challenge 
virus (virulent Wa) nor diarrheal illness (Yuan et al 2000). 
Subsequent studies in piglets suggested that 2/6 VLPs with 
adjuvant would supplement protection if given as a booster 
following an initial immunization with attenuated Wa virus 
(Nguyen et al 2006). VLP rotavirus vaccines have also been 
delivered intramuscularly to both mice and rabbits where 
they produced effective protection against fecal shedding 
(Bertolotti-Ciarlet et al 2003; Ciarlet et al 1998). Although 
protection induced by 2/6 VLPs in rabbits was enhanced by 
inclusion of VP4, this was not required for mice.
Vaccine candidates composed only of chimeric, E. coli-
expressed VP6 proteins from murine or human rotaviruses 
have been found to effectively protect mice against fecal 
rotavirus shedding when administered either intranasally, 
orally or intrarectally with effective adjuvants (Choi et al 
1999, 2002). The level of protection has been consistently 
 90% by any of these routes and protection was found to 
remain fully intact for at least one year. VP6 is the group 
antigen and, therefore, is highly conserved within group A 
rotaviruses. Thus, it is not surprising that protection elicited 
by intranasal immunization of adult mice with a human 
rotavirus VP6 protein was highly protective against fecal 
rotavirus shedding following challenge with heterotypic 
murine rotaviruses. Interestingly, protection elicited by 
intranasal immunization of neonatal mice with VP6 and 
adjuvant was delayed but eventually reached the level found 
after immunization of adult mice, a ﬁ  nding that may have 
relevance if this vaccine were administered to human neo-
nates (VanCott et al 2006).
Although anti-rotavirus antibodies have been identiﬁ  ed 
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with live rotaviruses (Franco and Greenberg 1995; McNeal 
et al 1995; VanCott et al 2006), this was not the case following 
mucosal immunization with VP6 and adjuvant. In this case, 
the only lymphocytes found to be required for protection were 
CD4+ T cells (McNeal et al 2002). Protection elicited by these 
effector cells was found to be associated with the intestinal pro-
duction of two cytokines, IL-17 and IFNγ (Smiley et al 2007), 
thus suggesting these cytokines may have direct or indirect 
roles in protection against rotavirus shedding. However, even 
in genetically-modiﬁ  ed mice that cannot, individually, make 
these proteins, full protection is still elicited after intranasal 
immunization with VP6 and adjuvant. Therefore, neither of 
these cytokines is required for protection, thus leaving the 
identity of the actual effectors of protection in doubt. Protec-
tion induced after intranasal immunization of mice with 2/6 
VLPs was also reported to depend on CD4+ T cells (Blutt et al 
2006). Thus, the primary effectors responsible for protection 
after oral immunization with live rotavirus and at least 2 of the 
non-living candidate vaccines appear to be quite different.
Although some of the most promising alternative rotavirus 
vaccine candidates for future development and evaluation are 
those classiﬁ  ed as non-living, there has been little consistent 
interest in, and funding available for, making this happen. 
The main reasons appear to be the lack of human clinical trial 
knowledge and the costs that are perceived to be needed to 
bring a non-living rotavirus vaccine into the marketplace. Pre-
sumably this would change dramatically if the use of another 
live rotavirus vaccine were stopped due to an unacceptable 
safety problem, something that no one wants.
Why are alternative rotavirus 
vaccines needed?
This question is one that when answered by 100 experts, will 
generate at least 90 different answers, all shaded in various 
ways to reﬂ  ect the particular experience and current position 
of the responder. Recognition of that will better allow the 
reader to incorporate statements made here on this question 
into their own experience before drawing conclusions. There 
are several historical facts that should be considered before 
addressing this question. The ﬁ  rst is that during the devel-
opment and licensing of Rotashield, development of other 
rotavirus vaccine candidates was on the distant horizon. Thus, 
the disappointment associated with its withdrawal from the 
USA market in 1999 was accentuated. The next rotavirus 
vaccine to be licensed was Rotarix in Mexico and its distri-
bution was not begun until 2005. Thus, co-development of 
multiple candidate rotavirus vaccines seemingly would have 
reduced this hiatus period.
However, the removal of any vaccine due to a safety issue 
would undoubtedly trigger a series of reactions that would 
affect other candidates, resulting in extended testing and 
delays in their licensure, and the greater the similarity of the 
two products, the greater would be the expected delay. Thus, 
even if either Rotarix or RotaTeq were approaching licensure 
in 1999, it was inevitable that much larger studies would 
have had to have been performed with these candidates to 
minimize the chances that they would also trigger intus-
susception. Presumably, other types of rotavirus vaccines, 
such as non-living candidates, would have come under less 
scrutiny regarding the same speciﬁ  c concern. However, that 
is not even certain. What does seem clear is that if another 
live, orally-deliverable rotavirus vaccine candidate is found 
to trigger intussusception, this entire class of vaccine can-
didates may be in jeopardy. This is why it was imperative 
that the two new rotavirus vaccines could not be licensed 
until it was established that the potential risk that they trig-
ger intussusception has been investigated and minimized. It 
remains unclear if a similar burden for large safety trials, as 
undertaken by the developers of Rotarix and RotaTeq will 
be expected of the developers of any new rotavirus vaccine 
candidates (eg, the UK bovine/human reassortant or the 
two human neonatal strains), a situation that may be very 
difﬁ  cult for the new manufacturers to support.
After reviewing the data generated in the two large safety 
studies (Ruiz-Palacios et al 2006; Vesikari, Karvonen, 
Majuri et al 2006), the WHO Global Committee for Vaccine 
Safety (GACVS) concluded that the licensed vaccines were 
safe within these clinical trial settings, ie, where the vaccines 
were given strictly according to a young age. However, the 
GACVS strongly recommended that post-marketing surveil-
lance for safety should be conducted in countries planning 
to introduce these vaccines. In addition, it was noted that 
strict compliance with a young age of administration in 
many developing countries would be extremely difﬁ  cult to 
implement. Therefore, the question of safety with regards to 
intussusception of live attenuated oral rotavirus vaccines, as 
a class action effect, remains unanswered today.
Another historical point of importance regarding the need 
for alternative rotavirus vaccines is ﬁ  nancial. Certainly a pur-
pose of the manufacturers of Rotarix and RotaTeq is to make 
a proﬁ  t and both have spent large amounts to reach where 
they are today. To recover their costs of development, they 
cannot give away their vaccines. Tiered pricing is already in 
effect as witnessed by the comparison of the cost of Rotarix 
in the private market of Europe vs. the public market in 
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at cost to countries in the developing world. However, even 
the price charged in Brazil will be unmanageable by most 
Third World nations unless the expense is supplemented by 
a donor agency such as the Global Alliance for Vaccines and 
Immunization (GAVI).
Three recent global developments have accelerated this 
supplementation process. First, the decision by the WHO 
to recommend rotavirus vaccine introduction in regions 
of the world where the clinical efﬁ  cacy of the vaccines 
have been demonstrated, ie, essentially in Latin America 
and Europe; secondly, the WHO approval of pre-qualiﬁ  -
cation status for Rotarix, with RotaTeq pre-qualiﬁ  cation 
likely during 2007; and thirdly, the decision by the GAVI 
Board to endorse funding for rotavirus vaccine purchase 
and introduction in resource poor countries in the regions 
recommended by WHO. All these developments contribute 
to help GAVI and UNICEF to purchase vaccines in those 
regions for eligible countries. However, at some point, this 
support is expected to cease and the nations themselves will 
be expected to pay the costs after the time of hand-over. The 
questions then are what will be these costs and will the poor 
nations be able to pay them? Historically, competition has 
driven down prices and there are ample examples of this with 
international vaccines. Thus, the development of alternative 
rotavirus vaccines could have this effect, especially if they 
were made in the developing nations themselves. This is at 
least one factor that has contributed to the funding of the 
116E and UK bovine/human reassortant vaccine candidates 
in developing nations. Perhaps the eventual production of 
these or other candidate vaccines will drive down prices. 
Since the costs associated with the production of rotavi-
rus vaccines will be related to their site of production, it 
is possible that if Rotarix or RotaTeq were produced in 
developing nations it could also help reduce the prices of 
these two vaccines. However, this would provide limited 
capacity building to the developing nation, a factor that 
is likely to less effectively control prices and continue 
the dependence of these nations on large pharmaceutical 
companies typically located in developed nations. It is 
also possible that the large multinational companies may 
be unable to supply all the rotavirus vaccine needed to 
immunize the world’s babies, something that is envisioned 
as necessary if the deaths due to rotavirus disease, 90% 
of which occur in these poor countries, are to be seriously 
curtailed. Local manufacturers in developing nations could 
make large contributions toward this end. Furthermore, 
the three countries with the largest birth cohorts (China, 
India and Indonesia) and with high rotavirus mortality do 
not classically import new vaccines. Thus, if alternative 
effective rotavirus vaccines were produced, licensed and 
made available only in these countries, there would still be 
a signiﬁ  cant reduction in rotavirus mortality globally.
Another question regarding alternative rotavirus vaccines 
now under development is whether they are signiﬁ  cantly 
different from the two being licensed today. Two of them 
(RV3 and 116E) are monovalent human rotavirus vaccines 
while the UK bovine/human reassortant vaccine is polyva-
lent. Thus, the ﬁ  rst two are more similar to Rotarix and the 
latter is similar to RotaTeq. Certainly the serotypes of the 
monovalent vaccines differ from the G1P[8] Rotarix strain 
and this or other properties of these strains could affect their 
individual safety, immunogencity and efﬁ  cacy features. 
These possible differences between monovalent vaccine 
candidates cannot be dismissed, just as potential differences 
between the properties of the bovine reassortant vaccines 
cannot be disregarded. However, it seems unlikely that any 
of the alternative candidates will offer signiﬁ  cant improve-
ments unless, for example, the reassortant UK bovine vaccine 
contains additional reassortant viruses not present in RotaTeq 
that are representative of emerging serotypes. Perhaps the 
use of a different immunization schedules with the alterna-
tive candidates, such as neonatal immunization, may increase 
their efﬁ  cacies over those of Rotarix and RotaTeq, but there 
is no data to support this hypothesis.
Planning for the future
The primary purpose of the “Meeting on Upstream Rotavirus 
Vaccines and Emerging Vaccine Producers” held at the WHO 
Headquarters in Geneva in March of 2006 was to obtain a 
consensus of opinion among many of the world leaders in 
rotavirus vaccine development regarding the need for alterna-
tive rotavirus vaccines and which should be given priority. 
Presentations were given by representatives of the companies 
(Merck and GlaxoSmithKline) that are manufacturing the 
two licensed vaccines being marketed worldwide today as 
well as by representatives of alternative living and non-living 
candidate rotavirus vaccines that are under development and 
developing world manufacturers who are potential producers 
of these vaccines. Upon closure of the meeting, there was 
general agreement that alternative vaccines are needed but 
the priority of reasons among attendees was highly variable. 
Although almost all clinical monies and efforts have been and 
are continuing to be directed toward live rotavirus vaccines, 
scientiﬁ  c logic suggests serious attention should be given to 
the non-living candidates. Opinions regarding prioritization 
of even the different live rotavirus vaccine candidates also Therapeutics and Clinical Risk Management 2008:4(1) 61
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varied, thus leaving their future funding and development 
uncertain. In the end, the ﬁ  eld will move forward, new vac-
cines will be developed, and world coverage will occur. The 
questions that remain are how long will this take and with 
what rotavirus vaccines.
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